Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments: 2015-2025

Historic Short-term Investments for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $197.6 million.

  • ImmunityBio's Short-term Investments rose 973.70% to $197.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $197.6 million, marking a year-over-year increase of 973.70%. This contributed to the annual value of $6.4 million for FY2024, which is 532.41% up from last year.
  • As of Q3 2025, ImmunityBio's Short-term Investments stood at $197.6 million, which was up 1,134.83% from $16.0 million recorded in Q2 2025.
  • ImmunityBio's 5-year Short-term Investments high stood at $197.6 million for Q3 2025, and its period low was $931,000 during Q1 2025.
  • Over the past 3 years, ImmunityBio's median Short-term Investments value was $11.8 million (recorded in 2023), while the average stood at $34.8 million.
  • Per our database at Business Quant, ImmunityBio's Short-term Investments tumbled by 98.21% in 2023 and then spiked by 3,489.67% in 2024.
  • Quarterly analysis of 5 years shows ImmunityBio's Short-term Investments stood at $136.0 million in 2021, then crashed by 98.13% to $2.5 million in 2022, then plummeted by 60.32% to $1.0 million in 2023, then spiked by 532.41% to $6.4 million in 2024, then soared by 973.70% to $197.6 million in 2025.
  • Its Short-term Investments was $197.6 million in Q3 2025, compared to $16.0 million in Q2 2025 and $931,000 in Q1 2025.